Arrowhead Pharmaceuticals, Inc. (ARWR)

NASDAQ: ARWR · IEX Real-Time Price · USD
33.74
+0.69 (2.09%)
Oct 3, 2022 4:00 PM EDT - Market closed
2.09%
Market Cap 3.57B
Revenue (ttm) 249.94M
Net Income (ttm) -153.93M
Shares Out 105.85M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE 111.11
Dividend n/a
Ex-Dividend Date n/a
Volume 596,046
Open 33.34
Previous Close 33.05
Day's Range 32.66 - 35.16
52-Week Range 26.81 - 84.83
Beta 1.41
Analysts Buy
Price Target 75.95 (+125.1%)
Earnings Date Nov 21, 2022

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Pha... [Read more...]

Industry Biotechnology
IPO Date Jun 16, 1993
CEO Christopher Anzalone
Employees 329
Stock Exchange NASDAQ
Ticker Symbol ARWR
Full Company Profile

Financial Performance

In 2021, ARWR's revenue was $138.29 million, an increase of 57.16% compared to the previous year's $87.99 million. Losses were -$140.85 million, 66.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is 75.95, which is an increase of 125.10% from the latest price.

Price Target
$75.95
(125.10% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: European Respiratory Soc...

1 month ago - Business Wire

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-M...

1 month ago - Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2022. The company is hosting a c...

1 month ago - Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2022, at 4:30 p.m. ET to discuss i...

2 months ago - Business Wire

Growth stocks remain resilient in weakening economy, says Neuberger's Jason Tauber

Jason Tauber, Neuberger Berman large cap disciplined growth and the disruptors portfolio manager, joins 'Closing Bell: Overtime' to discus his bullish case for the growth trade.

Other symbols: DHRDXCMEWLLYNBDS
2 months ago - CNBC Television

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 1, 2022, the Compe...

2 months ago - Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in two Phase 1/2a clinical trials of ARO-MUC5AC and ARO-RA...

2 months ago - Business Wire

Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Jou...

OSAKA, Japan & PASADENA, Calif.--(BUSINESS WIRE)--Results from Phase 2 Study of fazirsiran in patients with alpha-1 antitrypsin deficiency published in New England Journal of Medicine.

Other symbols: TAK
3 months ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Healthcare Conf...

3 months ago - Business Wire

Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a pulmonary research & development (R&D) Day today in New York City to discuss its emerging pipelin...

4 months ago - Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2022. The company is hosting a...

4 months ago - Business Wire

Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Victoria Vakiener, as an ...

5 months ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TIDES USA 2022: Oligonucleotide and...

5 months ago - Business Wire

Arrowhead Pharmaceuticals to Host Pulmonary R&D Day

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a pulmonary research & development (R&D) day to discuss its emerging pipeline of pulmon...

5 months ago - Business Wire

Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Fam...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the Phase 2 GATEWAY clinical study of investigational A...

5 months ago - Business Wire

Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market

PASADENA, Calif.--(BUSINESS WIRE)---- $ARWR--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has formed a joint venture, Visirna Therapeutics, with Vivo Capital to expand the reach...

5 months ago - Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 10, 2022, at 4:30 p.m. ET to discuss its financial...

5 months ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will present at April 2022 conferences including APASL 2022, AACR 2022, and Oligo22

6 months ago - Business Wire

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases

6 months ago - Business Wire

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma

6 months ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arrowhead Pharmaceuticals, Inc. -...

New York, New York--(Newsfile Corp. - March 2, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or the "Company") (NASDAQ: ARWR). Such...

7 months ago - Newsfile Corp

Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipi...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES-2 clinical study of ARO-ANG3 for mixed dyslipidemia

7 months ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) Investigation

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or "the Company") (NYSE: ARWR). In...

7 months ago - Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals doses first subjects in Phase 1/2 Study of ARO-C3, RNAi therapeutic for treatment of complement mediated diseases

7 months ago - Business Wire

Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead presented clinical data on ARO-HIF2 in patients with renal cell carcinoma at 2022 ASCO GU

7 months ago - Business Wire